Therapeutic Advances in Psychopharmacology
In PubMed through PubMed Central. Fully open access. Published by SAGE Publications for the British Association for Psychopharmacology.
Therapeutic Advances in Psychopharmacology publishes clinical psychopharmacology research, reviews and commentary for clinicians and researchers. Its scope includes drug treatment studies, therapeutic reviews and evidence synthesis across psychiatric conditions. It excludes preclinical laboratory and animal research.
Dr Robert BaxterPublishing in Therapeutic Advances in Psychopharmacology
Therapeutic Advances in Psychopharmacology is a fully open access Sage journal covering clinical psychopharmacology. It publishes clinical intervention and observation studies, reviews, evidence syntheses, case reports and scholarly comment. It excludes preclinical laboratory and animal research. Its guide also welcomes rigorous negative findings and offers two-stage registered reports.
Editorials are invitation-only and, like letters, have no article processing charge. Other accepted articles normally incur a $3,200 charge; standalone plain language summaries carry a higher fee. Waivers, discounts and institutional agreements may reduce the cost. The journal uses single-anonymised peer review, normally requiring two independent reviews before revision or acceptance, except for editorials and letters. It does not publish a submission-to-first-decision figure in the pages checked.
Free subscriber access
Unlock the author guide in one place
Word limits, abstract lengths and fees for each article type, member discounts and a checklist before you submit. Enter your email to unlock this journal and every other guide.
You'll also receive The Weekend Round every Saturday.- Original Articles
Clinical intervention or observation studies; around 6,000 words is recommended, with flexibility.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Review Articles
Usually commissioned, though unsolicited narrative, perspective and drug reviews are considered; 4,000 to 6,000 words recommended.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Scoping Reviews
Submit as Original Research and identify the scoping review in the title; follow PRISMA-ScR.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Systematic Reviews
Answer a defined question through a comprehensive evidence search; follow PRISMA.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Meta-analyses
Combine results from independent studies; follow PRISMA or MOOSE as appropriate.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Case Reports
Unusual cases need a literature review and clinical implications; follow CARE.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Case Series
Describe a small patient group with literature review and clinical implications; follow CARE.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Study Protocols
Forthcoming or ongoing studies must include applicable trial registration and ethics approval.
- Words
- —
- Abstract
- 300
- Figures & tables
- —
- References
- —
- Registered Reports, Pre-Data or Post-Data
Two-stage review accepts a proposal before data collection or analysis, then reviews completed results.
- Words
- —
- Abstract
- —
- Figures & tables
- —
- References
- —
- Brief reports
Concise original studies, including pilot, interim, secondary and robust negative findings.
- Words
- 2,000
- Abstract
- 150
- Figures & tables
- 2
- References
- 20
- Editorials
Invitation-only introductions or perspectives on the journal's subject or direction; no APC.
- Words
- 2,000
- Abstract
- —
- Figures & tables
- —
- References
- 20
- Letters to the Editor
Professional responses or alternative views on published articles; 500 words recommended and no APC.
- Words
- —
- Abstract
- —
- Figures & tables
- 1
- References
- 10
- Plain Language Summary of Publications (PLS-Ps)
Standalone, peer-reviewed, non-technical summary of a previously published article; separate $5,500 APC.
- Words
- —
- Abstract
- —
- Figures & tables
- —
- References
- —
Editorials and Letters to the Editor carry no APC; other accepted articles normally cost $3,200, and standalone Plain Language Summaries cost $5,500. APCs are payable after acceptance, with applicable taxes; there is no submission charge. Eligible corresponding authors in Research4Life Group A receive a full waiver, while Group B authors receive 50% off; institutional agreements and limited needs-based discounts may also apply.
Before you submit
- Use the appropriate EQUATOR checklist and upload it with the submission; scoping reviews need PRISMA-ScR.
- Register clinical trials by first participant enrolment and put registry details at the end of the abstract.
- Include every Statements and Declarations subheading, stating 'Not applicable' where needed.
- Supply a cover letter explaining suitability, plus a separate title page and anonymised manuscript.
- Give a preprint DOI at submission and do not update the preprint during peer review.
- Disclose AI use and acknowledge any third-party writing help in the manuscript and cover letter.
Frequently asked
- Is Therapeutic Advances in Psychopharmacology indexed in PubMed?
- Yes, through PubMed Central. Its articles are deposited in PMC and appear in PubMed with a PMID; it is not indexed in MEDLINE.
- How much does it cost to publish in Therapeutic Advances in Psychopharmacology?
- There is a free route: authors can publish without a fee.
- Does Therapeutic Advances in Psychopharmacology accept case reports?
- Yes. Therapeutic Advances in Psychopharmacology publishes case reports.
- What kind of peer review does Therapeutic Advances in Psychopharmacology use?
- Single-blind peer review.
